Patents Issued in January 26, 2016
  • Patent number: 9241884
    Abstract: Provided is a redispersible powder-dispersed cosmetic which has a clear supernatant when unused, can exhibit good powder redispersibility when shaken upon use, has a good sensation, e.g., smoothness and non-stickiness, upon application to the skin, and has an excellent effect of dissolving/removing keratotic plugs. The cosmetic is characterized by comprising (A) succinic acid and/or a salt thereof, (B) bentonite and (C) a hydrophilic surfactant. Particularly preferably, the cosmetic additionally comprises a cellulose powder. It is preferred that the component (A), i.e., succinic acid and/or the salt thereof, is contained in an amount of 0.01 to 10.0 mass % relative to the total amount of the cosmetic.
    Type: Grant
    Filed: December 25, 2012
    Date of Patent: January 26, 2016
    Assignee: SHISEIDO COMPANY, LTD.
    Inventors: Masayuki Shirao, Shigeru Mugikura
  • Patent number: 9241885
    Abstract: Disclosed are oral care compositions, including therapeutic rinses, especially mouthrinses and methods of use to provide significantly enhanced antimicrobial activity, thereby reducing oral bacteria and promoting overall oral health. The present compositions are formulated to deliver increased bioavailable levels of cationic antimicrobials, particularly quaternary ammonium compounds such as cetylpyridinium chloride (CPC) and are useful for preventing and treating diseases or conditions of the oral cavity including dental plaque, caries, gingivitis, periodontal disease and breath malodor. The present compositions are formulated to be essentially free of anionic, nonionic or amphoteric surfactants, which have been found to have a negative effect on bioavailability of the quaternary ammonium compounds and thus, their antimicrobial efficacy.
    Type: Grant
    Filed: January 18, 2005
    Date of Patent: January 26, 2016
    Assignee: THE PROCTER & GAMBLE COMPANY
    Inventors: Rebecca Lynn Roberge, Andrew Lee Wong
  • Patent number: 9241886
    Abstract: The present invention relates to a composition for dyeing keratin fibers, comprising:—one or more fatty substances,—one or more surfactants;—one or more oxidation bases,—one or more phenol-derived couplers corresponding to the formula (B2) below: * R1, R3, R5, represent a hydrogen; an optionally substituted C1-C8 alkyl or alkenyl radical; —SR or —OR; a saturated C5-C7 cyclic group; a (C1-C4)alkylcarbonyl group; hydrocarbonyl; a sulphonic or carboxylic acid group; * at least one of the radicals R1, R3, R5 representing a hydrogen atom; * R2, R4 represent a hydrogen; an optionally substituted C1-C8 alkyl or alkenyl; —SR; a (C1-C4)alkyl-carbonyl; hydrocarbonyl; a sulphonic or carboxylic acid group; * two groups chosen from R1, R2, R3, R4, R5 and borne by adjacent carbon atoms may form, together with said carbon atoms, a ring or a heterocycle with a single heteroatom, this ring or heterocycle comprising no double bond other than that of the ring to which it is fused; * at least one of the radicals R1, R2, R3, R4,
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: January 26, 2016
    Assignee: L'OREAL
    Inventors: Alain Lagrange, Marie Mignon
  • Patent number: 9241887
    Abstract: Systems and methods for skin rejuvenation are disclosed herein. In an embodiment, a skin rejuvenation system includes a unit dose of a booster product that includes active ingredients of ferulic acid and phloretin; a unit dose of at least one exfoliating product that includes active ingredients of ferulic acid and phloretin in combination with fruit acids or alpha hydroxyacids; and a unit dose of a nano-additive product for enhancing penetration of the active ingredients. A method for skin rejuvenation includes applying topically, to a skin surface to be treated, a booster product including active ingredients of ferulic acid and phloretin; applying topically, to the skin surface, at least one exfoliating product including active ingredients of ferulic acid and phloretin in combination with one of fruit acids or alpha hydroxyacids; and applying topically, to the skin surface, a nano-additive product for enhancing penetration of the active ingredients.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: January 26, 2016
    Assignee: Sesvalia USA, LLC
    Inventors: Gabriel Serrano Sanmiguel, Juan Manuel Serrano Nunez, Joaquin Melendez Zamora
  • Patent number: 9241888
    Abstract: The present invention relates to a cosmetic or pharmaceutical composition for treating alopecia, and in general for counteracting excessive hair loss, comprising as an active ingredient a compound of formula (I) R—N1-spermidine, or 1,4-butane-diamine,N-(3-aminopropyl)-N1—R. The compounds of general formula (I) are active in accordance with the objects of the present invention, and also sufficiently stable to allow effective application for topical use on the scalp without potentially being transformed into a different substance, which is no longer active, as a result of oxidation.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: January 26, 2016
    Assignee: Giuliani S.P.A.
    Inventors: Giammaria Giuliani, Ralf Paus, Anna Benedusi, Barbara Marzani, Sergio Baroni
  • Patent number: 9241889
    Abstract: This invention relates to the use of sodium dodecylbenzene sulphonate (SDDBS) for helping to prevent or remove surface deposited stains from natural teeth and dental prostheses and oral care compositions comprising SDDBS for such use.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: January 26, 2016
    Assignee: Glaxo Group Limited
    Inventors: Gail Cameron Aitken, David Raymond Churchley
  • Patent number: 9241890
    Abstract: The present invention relates to a topical composition, in particular a cosmetic and/or dermatological composition, to be used for preventing and/or treating stretch marks, including, in a physiologically acceptable medium, an effective amount of at least one synthetic polysulfated oligosaccharide having 1 to 4 glycose units, the salts thereof, and/or the derivatives thereof. The invention also relates to a cosmetic method, in particular for treating stretch marks, including at least one step of applying said composition to the skin.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: January 26, 2016
    Assignees: SOCIETE DE DEVELOPPEMENT ET DE RECHERCHE INDUSTRIELLE, LABORATOIRES URGO
    Inventors: Laurent Apert, Marielle Bouschbacher
  • Patent number: 9241891
    Abstract: Disclosed herein are personal care compositions having at least one oligopeptide self-assembled into nanofibers or macrostructures, wherein the oligopeptide is 2-20 amino acids in length, and wherein the oligopeptide has at least one 0- to 10-amino-acid block of hydrophobic amino acids alternating with at least one 1- to 10-amino-acid block of hydrophilic amino acid residues. The composition may further include a dermatologically acceptable carrier and at least one cosmetic skin care agent.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: January 26, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Conor David Whitehouse, Ellen Schmidt Baker, Ioannis Constantine Constantinides
  • Patent number: 9241892
    Abstract: Inventive embodiments disclosed herein relate to gel volume mascara. The mascara includes water in a concentration of at least about 45% by weight; disodium ethylenediaminetetraacetate; Polysorbate 20; Black iron oxide; One or more waxes selected from the group consisting of beeswax, Cera Carnauba/Copernicia Cerifera (Carnauba) Wax/CIRE de Carnauba, and paraffin in a concentration of 15-20% by weight; and a synthetic layered silicate, insoluble in water, in a concentration effective for forming a colloidal dispersion with the water.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 26, 2016
    Assignee: Coty Inc.
    Inventors: Nykol Allen, Julianne Sortino
  • Patent number: 9241893
    Abstract: Topical cosmetic compositions are provided that can comprise a Phyllanthus extract, a Bellis extract, and a licorice (Glycyrrhiza) extract. These compositions are used for topical cosmetic applications, particularly to lighten skin. Methods for lightening skin are also provided and can comprise topically administering a therapeutically effective amount of a topical cosmetic composition comprising a Phyllanthus extract, a Bellis extract, and a licorice extract, to skin of a subject in need thereof.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: January 26, 2016
    Assignee: Stiefel Laboratories, Inc.
    Inventors: Joao Paulo Caetano, Monica Alves Mariani De Oliveira
  • Patent number: 9241895
    Abstract: A composition for chemoembolotherapy of solid tumors comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: January 26, 2016
    Assignee: BIOCOMPATIBLES UK LIMITED
    Inventors: Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
  • Patent number: 9241896
    Abstract: Extended release formulations, methods of making, and methods of use, for example, in treatment of sialic acid deficiencies.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: January 26, 2016
    Assignee: ULTRAGENYX PHARMACEUTICAL INC.
    Inventor: Emil Kakkis
  • Patent number: 9241897
    Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: January 26, 2016
    Assignee: CSL BEHRING AG
    Inventors: Reinhard Franz Bolli, Werner Maeder, Peter Lerch
  • Patent number: 9241898
    Abstract: Polymeric nanoparticles encapsulating inhibitory ribonucleic acids (RNAs) and methods of their manufacture and use are provided. Advantageous properties of the nanoparticles include: 1) high encapsulation efficiency of inhibitory RNAs into the nanoparticles, 2) small size of the nanoparticles that increases cell internalization, and 3) sustained release of encapsulated inhibitory RNAs by the nanoparticles that allows for administration of an effective amount of inhibitory RNAs to cells or tissues over extended periods of time. Encapsulation efficiency of inhibitory RNAs into the nanoparticles is greatly increased by complexing the inhibitory RNAs to polycations prior to encapsulation. Methods of using the polymeric nanoparticles for treating or inhibiting diseases or disorders are provided.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: January 26, 2016
    Assignee: Yale University
    Inventors: W. Mark Saltzman, Kim Woodrow
  • Patent number: 9241899
    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of sexual dysfunction. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: January 26, 2016
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9241900
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: January 26, 2016
    Assignee: NOVALIQ GMBH
    Inventor: Clive G. Wilson
  • Patent number: 9241901
    Abstract: Embodiments of this invention generally relate to systems and methods for optical treatment and more particularly to non-invasive refractive treatment method based on sub wavelength particle implantation. In an embodiment, a method for optical treatment identifies an optical aberration of an eye, determines a dopant delivery device configuration in response to the optical aberration of the eye, wherein the determined dopant delivery device is configured to impose a desired correction to the eye to mitigate the identified optical aberration of the eye by applying a doping pattern to the eye so as to locally change a refractive index of the eye.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: January 26, 2016
    Assignee: AMO Wavefront Sciences, LLC
    Inventors: Thomas D. Raymond, Richard J. Copland
  • Patent number: 9241902
    Abstract: A soft chewable capsule film suitable for medicament or foodstuff encapsulation, and a method of fabricating capsules from such a film. Such capsules demonstrate fast rupture in the oral cavity, good mouth feel and chewability, and rapid dissolution of the shell components. In particular, the modified starch is substantially ungelatinized, due at least in part to the processing temperature, and may act as a water retention agent to promote hydration. Additionally, gelatins are selected for bloom strengths that result in a robust capsules that may be fabricated at a thinner wall thickness than previously experienced in the art. Accordingly, such thin capsules have a smaller mass than traditional capsules of the same size and dissolve more quickly than chewable capsules having greater thicknesses. The capsules may be fabricated by a rotary die process at speeds greater than those generally known for soft chewable capsules.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: January 26, 2016
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Dennis Rowe, Kelvin Royce Garnett
  • Patent number: 9241903
    Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: January 26, 2016
    Assignee: MannKind Corporation
    Inventors: Bryan R. Wilson, Marshall Grant
  • Patent number: 9241904
    Abstract: The present invention is related to metered dose inhalation formulas and manufacturing process. The active pharmaceutical ingredient can be beta-2 agonists, corticosteroids, or a combination thereof. The inhalation formulas are homogenized suspensions with hydrofluoroalkane (HFA) propellant, minimal amount of ethanol and polyetheleneglycol (PEG) as suspending and particle size modifying agents.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: January 26, 2016
    Assignee: INTECH BIOPHARM LTD.
    Inventors: Wei-Hsiu Wu, Yen-Chin Chao
  • Patent number: 9241905
    Abstract: A pharmaceutical suspension formulation comprising a dose greater than 100 mg/5 ml Cefixime and pharmaceutically acceptable excipients.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: January 26, 2016
    Assignee: LUPIN LIMITED
    Inventors: Sanjay Chhagan Wagh, Bharat Raghunath Metkar, Makarand Krishnakumar Avachat, Himadri Sen
  • Patent number: 9241906
    Abstract: This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: January 26, 2016
    Assignee: The Regents of the University of California
    Inventors: William R. Freeman, Michael J. Sailor, Lingyun Cheng
  • Patent number: 9241907
    Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: January 26, 2016
    Assignee: Curemark, LLC
    Inventors: Joan M. Fallon, Matthew Heil
  • Patent number: 9241908
    Abstract: The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: January 26, 2016
    Assignee: BIOCON LIMITED
    Inventors: Anand Khedkar, Sharath Kumar Mallapura Rangappa, Ramesh Subramani, Nitesh Dave, Devesh Radhakrishnan, Sundaresh Shankar, Sudheer Chivukula, Ranjith Ramakrishna, Shanmugam Thandava Murthy, Harish Venkatraman Pai, Nilanjan Sengupta, Ramakrishnan Melarkode, Harish Iyer
  • Patent number: 9241909
    Abstract: A pharmaceutical dosage form is provided that has a distinguishing characteristic and an identifier associated with the dosage form. The distinguishing characteristic is assigned from a limited set of distinguishing characteristics and is determined upon oral administration of the dosage form, or is detected in breath, bodily fluids, or tissues after ingestion, or injection or other non-oral administration. The identifier is associated with the dosage form and with the distinguishing characteristic. The identifier is associated with only one distinguishing characteristic but the distinguishing characteristic may be associated with multiple identifiers. The pharmaceutical dosage form may be used in a method to monitor compliance with a dosage regimen.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: January 26, 2016
    Inventor: Joel David Selanikio
  • Patent number: 9241910
    Abstract: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: January 26, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takashi Kurasawa, Yasuko Watanabe, Yoshihiro Omachi
  • Patent number: 9241911
    Abstract: A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: January 26, 2016
    Inventor: Fred H. Miller
  • Patent number: 9241912
    Abstract: The present invention relates to microcapsules comprising a polyurea shell and a core, which contains a pesticide, a water-immiscible solvent A and at least 5 wt % of an aprotic, polar solvent B, which has a solubility in water from 0.5 to 20 g/l at 20° C., based on the total weight of the solvents in the core. It further relates to microcapsules comprising a shell and a core, which contains a pesticide and 2-heptanone; to a method for preparing said microcapsules; to an aqueous composition comprising said microcapsules; and to a method for controlling phytopathogenic fungi and/or undesired plant growth and/or undesired attack by insects or mites and/or for regulating the growth of plants, with said microcapsules.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: January 26, 2016
    Assignee: BASF SE
    Inventors: Claude Taranta, Thomas Bork, Tina Schroeder-Grimonpont, Britta Katz, Tatjana Sikuljak, Simon Nord, Juergen Distler, Richard A. Warriner, Daniel Bihlmeyer, James Thomas Wofford
  • Patent number: 9241913
    Abstract: Gel nanoparticles for encapsulating and delivering a pharmaceutical compound to a patient. The nanoparticles are formed from N-trimethyl chitosan and polysialic acid, preferably in the presence of sodium tripolyphosphate. A ratio of polysialic acid to N-trimethyl chitosan of about 0.5 to 1 produces nanoparticles having diameter of about 100 nm (plus or minus 25 nm) and a zeta potential above 30 milivolts that can stability contain a pharmaceutical compound, such as methotrexate, for delivery to a patient.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: January 26, 2016
    Assignee: Syracuse University
    Inventor: Rebecca A. Bader
  • Patent number: 9241914
    Abstract: The present invention concerns a method of enhancing milk production by a ruminant that includes providing a feed that contains sorbitol and at least one additional feed component, and orally feeding the feed to the ruminant, the ruminant ingesting about 100 grams, or less, of sorbitol per day.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: January 26, 2016
    Assignee: Land O'Lakes, Inc.
    Inventor: Cindie M. Luhman
  • Patent number: 9241915
    Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: January 26, 2016
    Assignee: QuatRx Pharmaceuticals
    Inventor: Markku Anttila
  • Patent number: 9241916
    Abstract: Provided herein are methods and compositions for enhancing the cognitive performance of a subject in need thereof. A method may include administering to a subject an agent that increases the level of protein or activity of a sirtuin, such as SIRT1.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: January 26, 2016
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Li-Huei Tsai, Andre Fischer
  • Patent number: 9241917
    Abstract: The present invention discloses methods of use of facially amphiphilic polymers and oligomers, including pharmaceutical uses of the polymers and oligomers as antimicrobial agents and antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polymers and oligomers and their compositions, including pharmaceutical compositions. The present invention further discloses the design and synthesis of facially amphiphilic polymers and oligomers.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: January 26, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: William F. DeGrado, Gregory N. Tew, Michael L. Klein, Dahui Liu, Jing Yuan, Sungwook Choi
  • Patent number: 9241918
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: January 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Patent number: 9241919
    Abstract: Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast media (CM).
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: January 26, 2016
    Assignee: 3E THERAPEUTICS CORPORATION
    Inventors: Elliott C. Lasser, Kenneth H. Lasser
  • Patent number: 9241920
    Abstract: The present invention is directed to methods of inhibiting cancer cell proliferation, differentiation and/or survival. These methods involve the administration of Fbw7 E3 ligase inhibitors to inhibit c-Myc ubiquitination in cancerous cell populations, such as leukemic initiating cell populations, that are responsible for disease initiation and progression.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: January 26, 2016
    Assignee: NEW YORK UNIVERSITY
    Inventors: Iannis Aifantis, Linsey Reavie, Shannon Buckley
  • Patent number: 9241921
    Abstract: A composition comprising an active ingredient selected from the group of 5-aminolevulinic acid or a pharmaceutically acceptable salt or derivative thereof; and an aqueous carrier comprising at least one absorption enhancer, an anesthetic, hyaluronic acid and at least one acid selected from the group consisting of glycolic acid and lactic acid. The composition is useful in a photodynamic method of treating skin disorders.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: January 26, 2016
    Inventor: Pankaj Modi
  • Patent number: 9241922
    Abstract: A pharmaceutical solution of taxanes, its preparation method, a composition comprising said solution and its pharmaceutical combination package are disclosed. Said pharmaceutical solution comprises taxanes, a pH regulator and a solvent, wherein the pH regulator is a water-soluble acid.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: January 26, 2016
    Assignee: Tasly Holding Group Co., Ltd.
    Inventors: Jianming Chen, Baoan Gao, Li Deng, Qiuxia Yang, Jing Sun, Wei Liu, Peng Gu, Yingying Zhang, Jialiang Zhang
  • Patent number: 9241923
    Abstract: The present disclosure is directed to methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising a neurologic component, wherein the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include lactoferrin, zinc sulfate, one or more organosulfur compounds, and mixtures thereof.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: January 26, 2016
    Assignee: Mead Johnson Nutrition Company
    Inventors: Chenzhong Kuang, Yan Xiao, Eduard Poels, Zeina Jouni, Dirk Hondmann
  • Patent number: 9241924
    Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: January 26, 2016
    Assignee: CYMABAY THERAPEUTICS, INC.
    Inventors: Charles A. McWherter, Robert Louis Martin, David B. Karpf, Brian K. Roberts, Douglas Alan Lorenz, Rodney James Ketner
  • Patent number: 9241925
    Abstract: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: January 26, 2016
    Assignee: Dart NeuroScience LLC
    Inventors: Timothy P. Tully, Filippo Cavalieri, Rusiko Bourtchouladze
  • Patent number: 9241926
    Abstract: A method of treating a human subject in need of melatonin therapy comprises administering to a human subject a composition comprising melatonin dispersed in a polymer matrix adapted to cover the melatonin in a melatonin solubility enhancing pH environment after ingestion and to maintain the melatonin solubility enhancing pH environment when said composition is present in said subject's intestines so that an effective amount of melatonin is released into the subject's intestines.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: January 26, 2016
    Assignee: Zx Pharma, LLC
    Inventors: Syed Shah, Daniel Hassan
  • Patent number: 9241927
    Abstract: The present invention relates to a pharmaceutical composition that comprises a compound of formula (I) as active pharmaceutical ingredient: or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof; and at least a pharmaceutically acceptable excipient, wherein the active pharmaceutical ingredient is present in an amount of at least 80% of the total dry weight of the composition.
    Type: Grant
    Filed: November 25, 2010
    Date of Patent: January 26, 2016
    Assignee: Laboratories Del Dr, Esteve, S.A.
    Inventors: Luis Soler Ranzani, Pierandrea Esposito, Gemma Casadevall Pujals, Nuria Cubel Suñé
  • Patent number: 9241928
    Abstract: This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in inhibiting the ability of a bacterium to kill a host organism, as well as methods for using these compounds for treating bacterial infections.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: January 26, 2016
    Assignees: The General Hospital Corporation, Northeastern University
    Inventors: Terence Moy, Annie Conery, Kim Lewis, Frederick M. Ausubel, Read Pukkila-Worley
  • Patent number: 9241929
    Abstract: An object of the present invention is to provide a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation. The prophylactic or ameliorating agent used in the present invention is a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation, wherein the prophylactic or ameliorating agent contains a compound having a molecular weight of 1500 or lower.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: January 26, 2016
    Inventors: Masatoshi Hagiwara, Masafumi Matsuo, Naoyuki Kataoka, Atsushi Nishida
  • Patent number: 9241930
    Abstract: Substituted perhydro pyrrolopyridines and methods for their use in the treatment of HIV infections, AIDS, and AIDS-related diseases, and in the treatment of BVDV infections are described herein. Also, pharmaceutical compositions comprising the substituted perhydro pyrrolopyridines are useful for the treatment of HIV infections, AIDS, and AIDS-related diseases. The compositions include one or more carriers, diluents, or excipients, or a combination thereof.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: January 26, 2016
    Assignee: NovaDrug, LLC
    Inventor: Eliezer Huberman
  • Patent number: 9241931
    Abstract: A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: January 26, 2016
    Assignee: GALAPAGOS NV
    Inventors: Christel Jeanne Marie Menet, Alastair James Hodges, Huw David Vater
  • Patent number: 9241932
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: January 26, 2016
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Patent number: 9241933
    Abstract: The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: January 26, 2016
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov, Rodolphe Hajj
  • Patent number: 9241934
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: January 26, 2016
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Rossitza Gueorguieva Alargova, Ritu Rohit Kaushik, Irina Nikolaevna Kadiyala, Christopher Young